阿托伐他汀联合替罗非班治疗冠心病PCI术后患者的疗效观察

Efficacy observation of atorvastatin combined with tirofiban in the treatment of patients with coronary heart disease after PCI

目的探究阿托伐他汀联合替罗非班治疗冠心病经皮冠状动脉介入治疗(PCI)术后患者的临床疗效。方法98例行PCI的冠心病患者,随机分为对照组(50例)与观察组(48例)。对照组采用阿托伐他汀治疗,观察组采用阿托伐他汀联合替罗非班治疗。对比两组患者不良事件发生情况及治疗效果。结果观察组不良事件发生率4.17%低于对照组的24.00%,差异有统计学意义(P<0.05)。观察组治疗总有效率95.83%高于对照组的78.00%,差异有统计学意义(P<0.05)。结论阿托伐他汀联合替罗非班对冠心病PCI术后患者治疗效果明显,可减少不良事件发生率,预防支架内再狭窄,预后效果明显。

Objective To investigate the clinical efficacy of atorvastatin combined with tirofiban in the treatment of patients with coronary heart disease after percutaneous coronary intervention(PCI).Methods A total of 98 patients with coronary heart disease treated by PCI were randomly divided into the control group(50 cases)and the observation group(48 cases).The control group was treated with atorvastatin,and the observation group was treated with atorvastatin combined with tirofiban.The incidence of adverse events and therapeutic effects were compared between the two groups.Results The incidence of adverse events 4.17%in the observation group was lower than 24.00%in the control group,and the difference was statistically significant(P<0.05).The total effective rate 95.83%of the observation group was higher than 78.00%of the control group,and the difference was statistically significant(P<0.05).Conclusion Atorvastatin combined with tirofiban has obvious therapeutic effect on patients with coronary heart disease after PCI,and can reduce the incidence of adverse events,prevent in-stent restenosis,and has obvious prognostic effect.